Please use this identifier to cite or link to this item:
Title: Effect of progestogens on estrogen-induced lipoprotein changes
Authors: Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı
Tüfekçi, Mehpare
Zafer, Çolak
Ozan, Hakan
Kimya, Yalçın
Aydınlar, Ali
Keywords: Hormone replacement
Hormone replacement therapy
Post-menopausal women
Endometrial cancer
Obstetrics & gynecology
Reproductive biology
Issue Date: 1993
Publisher: Elsevier Science Bv
Citation: Tüfekçi, M. vd. (1993). ''Effect of progestogens on estrogen-induced lipoprotein changes''. European Journal of Obstetrics & Gynecology and Reproductive Biology, 49(3), 169-174.
Abstract: A study was performed to evaluate the role of progestogens, on estrogen-induced changes in lipoprotein levels. Sixty postmenopausal symptomatic women, aged 36-59, were included in the study. They were prospectively randomized to a sequential schedule (n = 20), 17beta-estradiol transdermally 0.05 mg/day on days 1-24 and medroxyprogesterone acetate 10 mg/day orally on days 15-24 or a continuous schedule (n = 20), 17beta-estradiol transdermally 0.05 mg/day and medroxyprogesterone acetate 2.5 mg/day orally on days 1-24. Patients who had total abdominal hysterectomy + bilateral salphingooopherectomy (n = 20) received only 17beta-estradiol 0.05 mg/day continuously. Serum total cholesterol (TC), high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglyceride (TG) levels were determined prior to and at the 3rd, 6th and 9th month of therapy in all groups. Mean TC, TG and LDL cholesterol levels did not change significantly during therapy (P > 0.05). Only the mean HDL cholesterol levels showed significant increases in all groups; from 42.30 +/- 9.97 mg/dl to 64.10 +/- 6.81 mg/dl in group I (P < 0.001), from 41.85 +/- 9.09 mg/dl to 60.65 +/- 7.41 mg/dl in group II (P < 0.001) and from 40.70 +/- 11.26 mg/dl to 58.80 +/- 7.74 mg/dl in group III (P < 0.001). It is concluded that medroxyprogesterone acetate, whether used continuously or sequentially, does not oppose the beneficial effects of transdermal 17beta-estradiol on the lipoprotein profile.
ISSN: 0301-2115
Appears in Collections:Web of Science

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.